Evidence map›Paper›PMID 25803611›Full record

ArticlePloS one2015

A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.

Edward Rockenstein, Cassia R Overk, Kiren Ubhi, Michael Mante, Christina Patrick, Anthony Adame, Alejandro Bisquert, Margarita Trejo-Morales, Brian Spencer, Eliezer Masliah

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Brain communications · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Modeling neurological disorders using brain organoids.Seminars in cell & developmental biology · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Tau in neurodegenerative disease.Annals of translational medicine · 2018
    Review
  17. SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Edward RockensteinDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Cassia R OverkDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Kiren UbhiDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Michael ManteDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Christina PatrickDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Anthony AdameDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Alejandro BisquertDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Margarita Trejo-MoralesDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Brian SpencerDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America.
Eliezer MasliahDepartment of Neurosciences, University of California San Diego, La Jolla, California, United States of America; Department of Pathology, University of California San Diego, La Jolla, California, United States of America.
University of California, San Diego · US

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
Viral VectorsP01AG010435 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUSZYNSKI, MARK H. · 1991 to 2014
$20.9M
La Jolla Interdisciplinary Neuroscience Center Cores - Vital VP30NS057096 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI LIPTON, STUART A · 2006 to 2010
$12.7M
Studies on Diagnosis, Pathophysiology, and Treatment of Autonomic Failure in MSAP01NS044233 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOW, PHILLIP A · 2003 to 2014
$12.4M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
Transgenic Models to Study Alzheimer's DiseaseR37AG011385 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2002 to 2011
$4.9M
TRANSGENIC MODELS TO SUDY ALZHEIMERS DISEASER01AG011385 · NIA · SCRIPPS RESEARCH INSTITUTE · PI MUCKE, LENNART · 1992 to 2017
$3.2M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
NIA NIH HHS AG010435NIA NIH HHS AG011385NIA NIH HHS AG18440NIA NIH HHS P01 AG010435NIA NIH HHS P50 AG005131NIA NIH HHS R01 AG011385NIA NIH HHS R01 AG018440NIA NIH HHS R37 AG011385NIA NIH HHS R37 AG018440NINDS NIH HHS NS044233NINDS NIH HHS NS057096NINDS NIH HHS P01 NS044233NINDS NIH HHS P30 NS057096
6 · The paper itself

Abstract

Tauopathies are a group of disorders leading to cognitive and behavioral impairment in the aging population. While four-repeat (4R) Tau is more abundant in corticobasal degeneration, progressive supranuclear palsy, and Alzheimer's disease, three-repeat (3R) Tau is the most abundant splice, in Pick's disease. A number of transgenic models expressing wild-type and mutant forms of the 4R Tau have been developed. However, few models of three-repeat Tau are available. A transgenic mouse model expressing three-repeat Tau was developed bearing the mutations associated with familial forms of Pick's disease (L266V and G272V mutations). Two lines expressing high (Line 13) and low (Line 2) levels of the three-repeat mutant Tau were analyzed. By Western blot, using antibodies specific to three-repeat Tau, Line 13 expressed 5-times more Tau than Line 2. The Tau expressed by these mice was most abundant in the frontal-temporal cortex and limbic system and was phosphorylated at residues detected by the PHF-1, AT8, CP9 and CP13 antibodies. The higher-expressing mice displayed hyperactivity, memory deficits in the water maze and alterations in the round beam. The behavioral deficits started at 6-8 months of age and were associated with a progressive increase in the accumulation of 3R Tau. By immunocytochemistry, mice from Line 13 displayed extensive accumulation of 3R Tau in neuronal cells bodies in the pyramidal neurons of the neocortex, CA1-3 regions, and dentate gyrus of the hippocampus. Aggregates in the granular cells had a globus appearance and mimic Pick's-like inclusions. There were abundant dystrophic neurites, astrogliosis and synapto-dendritic damage in the neocortex and hippocampus of the higher expresser line. The hippocampal lesions were moderately argyrophilic and Thioflavin-S negative. By electron microscopy, discrete straight filament aggregates were detected in some neurons in the hippocampus. This model holds promise for better understanding the natural history and progression of 3R tauopathies and their relationship with mitochondrial alterations and might be suitable for therapeutical testing.

Indexed as

Disease Models, AnimalPick Disease of the BrainRepetitive Sequences, Amino AcidTauopathiesAnimalsAxonsBehavior, AnimalGene Expression RegulationHippocampusHumansIntermediate FilamentsMemoryMiceMice, TransgenicMitochondriaNeocortexRNA, Messengertau Proteins

Identifiers

PMID25803611
PMCPMC4372415
OpenAlexW2001069482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.